Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polyps.
SNOT-22
biomarker
chronic rhinosinusitis
endoscopic sinus surgery
eosinophilic rhinitis and nasal polyposis
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
revised:
28
11
2023
received:
15
07
2023
accepted:
28
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
24
1
2024
Statut:
aheadofprint
Résumé
Chronic rhinosinusitis with nasal polyps (CRSwNP) may have a heterogeneous response to medical/surgical treatments based on endotypes. Data correlating biomarkers and severity of the disease are lacking. We aimed to determine if IL-5 and calprotectin may be useful in defining severity of disease and identifying uncontrolled patients. This was a case-control study including 81 patients with diffuse CRSwNP who underwent at least one previous surgery and treated with intranasal steroids. We enrolled 39 uncontrolled patients (SNOT-22 ≥ 40 and two or more cycles of systemic corticosteroids in last year) (Group A) and 42 controlled one (SNOT-22 < 40 and less than two cycles of systemic corticosteroids in last year) (Group B). We analyzed IL-5 and calprotectin in both nasal secretions and nasal polyp tissue. Calprotectin and IL-5 were significantly higher in Group A in both secretions and tissue, and the higher the number of previous surgeries, the higher the levels detected in nasal secretions. At univariate analyses, smoking, asthma, non-steroidal anti-inflammatory drugs-exacerbated respiratory disease (NSAID-ERD), blood eosinophilia, neutrophils, and eosinophils at nasal cytology were significantly associated with uncontrolled disease. Multivariate analyses showed that asthma, NSAID-ERD, and IL-5 in nasal secretion/polyp tissue were significantly related to the risk of uncontrolled disease. Our data suggest that asthma, NSAID-ERD, and IL-5 in nasal secretions/tissue may be helpful to identify more severe patients, as they are related to the risk of uncontrolled disease. Nonetheless, high levels of calprotectin and neutrophilia were also observed in uncontrolled patients, especially after multiple surgeries.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic rhinosinusitis with nasal polyps (CRSwNP) may have a heterogeneous response to medical/surgical treatments based on endotypes. Data correlating biomarkers and severity of the disease are lacking. We aimed to determine if IL-5 and calprotectin may be useful in defining severity of disease and identifying uncontrolled patients.
METHODS
METHODS
This was a case-control study including 81 patients with diffuse CRSwNP who underwent at least one previous surgery and treated with intranasal steroids. We enrolled 39 uncontrolled patients (SNOT-22 ≥ 40 and two or more cycles of systemic corticosteroids in last year) (Group A) and 42 controlled one (SNOT-22 < 40 and less than two cycles of systemic corticosteroids in last year) (Group B). We analyzed IL-5 and calprotectin in both nasal secretions and nasal polyp tissue.
RESULTS
RESULTS
Calprotectin and IL-5 were significantly higher in Group A in both secretions and tissue, and the higher the number of previous surgeries, the higher the levels detected in nasal secretions. At univariate analyses, smoking, asthma, non-steroidal anti-inflammatory drugs-exacerbated respiratory disease (NSAID-ERD), blood eosinophilia, neutrophils, and eosinophils at nasal cytology were significantly associated with uncontrolled disease. Multivariate analyses showed that asthma, NSAID-ERD, and IL-5 in nasal secretion/polyp tissue were significantly related to the risk of uncontrolled disease.
CONCLUSIONS
CONCLUSIONS
Our data suggest that asthma, NSAID-ERD, and IL-5 in nasal secretions/tissue may be helpful to identify more severe patients, as they are related to the risk of uncontrolled disease. Nonetheless, high levels of calprotectin and neutrophilia were also observed in uncontrolled patients, especially after multiple surgeries.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. International Forum of Allergy & Rhinology published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society.
Références
De Corso E, Bellocchi G, De Benedetto M, et al. Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology. Acta Otorhinolaryngol Ital. 2022;42(1):1-16. doi:10.14639/0392-100X-N1614
De Corso E, Furneri G, Salsi D, et al. Cost-utility analysis of dupilumab for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Italy. J Pers Med. 2022;12(6):951. doi:10.3390/jpm12060951
Rahman T, Alam MM, Ahmed S, Karim MA, Rahman M, Wahiduzzaman M. Outcome of endoscopic sinus surgery in the treatment of chronic rhinosinusitis. Mymensingh Med J. 2016;25(2):261-270.
De Corso E, Pipolo C, Cantone E, et al. Practical recommendations for managing severe chronic rhinosinusitis with nasal polyps in the era of biologics. Acta Otorhinolaryngol Ital. 2023;43(5):324-340. doi:10.14639/0392-100X-N2422
Hellings PW, Fokkens WJ, Orlandi R, et al. The EUFOREA pocket guide for chronic rhinosinusitis. Rhinology. 2023;61(1):85-89. doi:10.4193/Rhin22.344
Kim DK, Eun KM, Kim MK, et al. Comparison between signature cytokines of nasal tissues in subtypes of chronic rhinosinusitis. Allergy Asthma Immunol Res. 2019;11(2):201-211. doi:10.4168/aair.2019.11.2.201
De Corso E, Baroni S, Settimi S, et al. Sinonasal biomarkers defining type 2-high and type 2-low inflammation in chronic rhinosinusitis with nasal polyps. J Pers Med. 2022;12(8):1251. doi:10.3390/jpm12081251
De Corso E, Seccia V, Ottaviano G, et al. Clinical evidence of type 2 inflammation in non-allergic rhinitis with eosinophilia syndrome: a systematic review. Curr Allergy Asthma Rep. 2022;22(4):29-42. doi:10.1007/s11882-022-01027-0
De Corso E, Baroni S, Onori ME, et al. Calprotectin in nasal secretion: a new biomarker of non-type 2 inflammation in CRSwNP. Acta Otorhinolaryngol Ital. 2022;42(4):355-363. doi:10.14639/0392-100X-N1800
Wang Z, Wang Q, Duan S, et al. A diagnostic model for predicting type 2 nasal polyps using biomarkers in nasal secretion. Front Immunol. 2022;13:1054201. doi:10.3389/fimmu.2022.1054201
Förster-Ruhrmann U, Szczepek AJ, Pierchalla G, et al. Chemokine expression-based endotype clustering of chronic rhinosinusitis. J Pers Med. 2022;12(4):646. doi:10.3390/jpm12040646
Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(S29):1-464. doi:10.4193/Rhin20.600
Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023;61(3):194-202. doi:10.4193/Rhin22.489
De Corso E, Baroni S, Lucidi D, et al. Nasal lavage levels of granulocyte-macrophage colony-stimulating factor and chronic nasal hypereosinophilia. Int Forum Allergy Rhinol. 2015;5(6):557-562. doi:10.1002/alr.21519
Mozzanica F, Preti A, Gera R, et al. Cross-cultural adaptation and validation of the SNOT-22 into Italian [published correction appears in Eur Arch Otorhinolaryngol. 2022;279(7):3753-3754]. Eur Arch Otorhinolaryngol. 2017;274(2):887-895. doi:10.1007/s00405-016-4313-x
De Corso E, Lucidi D, Battista M, et al. Prognostic value of nasal cytology and clinical factors in nasal polyps development in patients at risk: can the beginning predict the end? Int Forum Allergy Rhinol. 2017;7(9):861-867. doi:10.1002/alr.21979
Gelardi M, Iannuzzi L, De Giosa M, et al. Non-surgical management of chronic rhinosinusitis with nasal polyps based on clinical-cytological grading: a precision medicine-based approach. Trattamento medico della rinosinusite cronica con poliposi naso-sinusale sulla base del sistema di grading clinico-citologico per un approccio medico personalizzato. Acta Otorhinolaryngol Ital. 2017;37(1):38-45. doi:10.14639/0392-100X-1417
De Corso E, Baroni S, Battista M, et al. Nasal fluid release of eotaxin-3 and eotaxin-2 in persistent sinonasal eosinophilic inflammation. Int Forum Allergy Rhinol. 2014;4(8):617-624. doi:10.1002/alr.21348
De Corso E, Baroni S, Romitelli F, et al. Nasal lavage CCL24 levels correlate with eosinophils trafficking and symptoms in chronic sino-nasal eosinophilic inflammation. Rhinology. 2011;49(2):174-179. doi:10.4193/Rhino10.133
Watelet JB, Gevaert P, Holtappels G, Van Cauwenberge P, Bachert C. Collection of nasal secretions for immunological analysis. Eur Arch Otorhinolaryngol. 2004;261(5):242-246. doi:10.1007/s00405-003-0691-y
De Corso E, Anzivino R, Galli J, et al. Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. Laryngoscope. 2019;129(3):551-557. doi:10.1002/lary.27576
Wouthuyzen-Bakker M, Ploegmakers JJW, Kampinga GA, Wagenmakers-Huizenga L, Jutte PC, Muller Kobold AC. Synovial calprotectin: a potential biomarker to exclude a prosthetic joint infection. Bone Joint J. 2017;99-B(5):660-665. doi:10.1302/0301-620X.99B5.BJJ-2016-0913.R2
Oh SH, Choi YB, Kim JH, Weihl CC, Ju JS. Quantification of autophagy flux using LC3 ELISA. Anal Biochem. 2017;530:57-67. doi:10.1016/j.ab.2017.05.003
De Corso E, Pasquini E, Trimarchi M, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy. 2023;78(10):2669-2683. doi:10.1111/all.15772
Ottaviano G, De Corso E, Cantone E, et al. Measuring nasal patency and the sense of smell in CRSwNP patients treated with dupilumab. J Pers Med. 2023;13(2):234. doi:10.3390/jpm13020234
Cantone E, De Corso E, Ricciardiello F, et al. Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP. J Pers Med. 2022;12(8):1215. doi:10.3390/jpm12081215
De Corso E, Settimi S, Montuori C, et al. Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a “real-life” observational study in the first year of treatment. J Clin Med. 2022;11(10):2684. doi:10.3390/jcm11102684
Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: european position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12. doi:10.4193/Rhino12.000
Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15(3):508. doi:10.1007/s11882-014-0508-7
López-Chacón M, Mullol J, Pujols L. Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis. Curr Allergy Asthma Rep. 2015;15(5):19. doi:10.1007/s11882-015-0520-6
Wu AW, Ting JY, Platt MP, Tierney HT, Metson R. Factors affecting time to revision sinus surgery for nasal polyps: a 25-year experience. Laryngoscope. 2014;124(1):29-33. doi:10.1002/lary.24213
De Corso E, Settimi S, Montuori C, et al. How to manage recurrences after surgery in CRSwNP patients in the biologic era: a narrative review. Acta Otorhinolaryngol Ital. 2023;43(1):S3-S13. doi:10.14639/0392-100X-suppl.1-43-2023-01
Medrek SK, Parulekar AD, Hanania NA. Predictive biomarkers for asthma therapy. Curr Allergy Asthma Rep. 2017;17(10):69. doi:10.1007/s11882-017-0739-5
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials [published correction appears in Lancet. 2019;394(10209):1618]. Lancet. 2019;394(10209):1638-1650. doi:10.1016/S0140-6736(19)31881-1
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519-531. doi:10.1038/nri3024
Kong IG, Kim DW. Pathogenesis of recalcitrant chronic rhinosinusitis: the emerging role of innate immune cells. Immune Netw. 2018;18(2):e6. doi:10.4110/in.2018.18.e6
Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. 2009;124(3):478-484.e1-2. doi:10.1016/j.jaci.2009.05.017
Kim DK, Lim HS, Eun KM, et al. Subepithelial neutrophil infiltration as a predictor of the surgical outcome of chronic rhinosinusitis with nasal polyps. Rhinology. 2021;59(2):173-180. doi:10.4193/Rhin20.373
Wen W, Liu W, Zhang L, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol. 2012;129(6):1522-1528.e5. doi:10.1016/j.jaci.2012.01.079
Clancy DM, Henry CM, Sullivan GP, Martin SJ. Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines. FEBS J. 2017;284(11):1712-1725. doi:10.1111/febs.14075
Teufelberger AR, Nordengrün M, Braun H, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol. 2018;141(2):549-559.e7. doi:10.1016/j.jaci.2017.05.004
Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood. 2016;127(18):2173-2181. doi:10.1182/blood-2016-01-688887
Wang X, Du J, Zhao C. Bacterial biofilms are associated with inflammatory cells infiltration and the innate immunity in chronic rhinosinusitis with or without nasal polyps. Inflammation. 2014;37(3):871-879. doi:10.1007/s10753-013-9807-8
Chalermwatanachai T, Zhang N, Holtappels G, Bachert C. Association of mucosal organisms with patterns of inflammation in chronic rhinosinusitis. PLoS One. 2015;10(8):e0136068. doi:10.1371/journal.pone.0136068
Tieu DD, Peters AT, Carter RG, et al. Evidence for diminished levels of epithelial psoriasin and calprotectin in chronic rhinosinusitis [published correction appears in J Allergy Clin Immunol. 2010;126(6):1169]. J Allergy Clin Immunol. 2010;125(3):667-675. doi:10.1016/j.jaci.2009.11.045
Van Crombruggen K, Vogl T, Pérez-Novo C, Holtappels G, Bachert C. Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue. Eur Respir J. 2016;47(1):264-274. doi:10.1183/13993003.00159-2015
De Corso E, Settimi S, Tricarico L, et al. Predictors of disease control after endoscopic sinus surgery plus long-term local corticosteroids in CRSwNP. Am J Rhinol Allergy. 2021;35(1):77-85. doi:10.1177/1945892420936196